Table 3.
Comparison of effects of itraconazole with the prednisolone on demographic and clinical findings of severe asthma
| Total |
Before trial
|
After one month
|
After 4 months
|
|||
|---|---|---|---|---|---|---|
| Itraconazole | Prednisolone | Itraconazole | Prednisolone | Itraconazole | ||
| Cough | 92 (94%) | 49 (96%) | 43 (90%) | 30 (59%)‡ | 38 (78%) | 24 (48%)‡ |
| Dyspnea | 96 (96%) | 50 (98%) | 46 (94%) | 31 (62%)†‡ | 48 (100%) | 26 (52%)‡ |
| Sound on chest | 95 (95%) | 49 (96%) | 46 (94%) | 26 (53%)‡ | 38 (78%) | 22 (44%)‡ |
| Sputum | 44 (86%) | 44 (86%) | 33 (68%) | 24 (47%)‡ | 36 (75%) | 26 (50%)‡ |
| Chest pain | 62 (62%) | 37 (77%)* | 25 (52%) | 16 (30%)‡ | 21 (42%) | 17 (33%)‡ |
| Wheezing | 88 (89%) | 45 (98%) | 43 (90%) | 15 (34%)†‡ | 43 (88%) | 14 (30%)‡ |
| Night symptoms | 86 (86%) | 43 (87%) | 43 (89%) | 15 (30%)† | 28 (56%) | 6 (12%)‡ |
| Fever | 22 (22%) | 6 (12%)* | 16 (32%) | 4 (8%) | 12 (23%) | 2 (4%) |
| Sweating | 61 (61%) | 33 (65%) | 28 (58%) | 33 (65%) | 38 (78%) | 22 (44%) |
| Myalgia | 84 (84%) | 43 (84%) | 41 (84%) | 29 (57%)‡ | 32 (66%) | 26 (52%)‡ |
AHR= Airway hyper-responsiveness, GERD= Gastero-esophageal reflux, PND= Post- nasal drip
*= Significant difference between case and control groups before the trial (chi square test)
†= Significant difference between case and the control groups after the trial (chi square test)
‡= Significant difference after the treatment with Itraconazole
(McNemar test)